SG11202111304UA - 4h-pyrrolo[3,2-c]pyridin-4-one compounds - Google Patents
4h-pyrrolo[3,2-c]pyridin-4-one compoundsInfo
- Publication number
- SG11202111304UA SG11202111304UA SG11202111304UA SG11202111304UA SG11202111304UA SG 11202111304U A SG11202111304U A SG 11202111304UA SG 11202111304U A SG11202111304U A SG 11202111304UA SG 11202111304U A SG11202111304U A SG 11202111304UA SG 11202111304U A SG11202111304U A SG 11202111304UA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrrolo
- pyridin
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838051P | 2019-04-24 | 2019-04-24 | |
| US201962940036P | 2019-11-25 | 2019-11-25 | |
| PCT/EP2020/061176 WO2020216781A1 (en) | 2019-04-24 | 2020-04-22 | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111304UA true SG11202111304UA (en) | 2021-11-29 |
Family
ID=70456765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111304UA SG11202111304UA (en) | 2019-04-24 | 2020-04-22 | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
Country Status (23)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081486A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | 4H-PYRROLO [3,2-C] PYRIDIN-4-ONE DERIVATIVES |
| EP3958865A1 (en) | 2019-04-24 | 2022-03-02 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN115836070B (zh) * | 2020-08-10 | 2024-08-09 | 上海和誉生物医药科技有限公司 | 作为egfr抑制剂的稠环化合物及其制备方法和应用 |
| CA3196712A1 (en) * | 2020-09-23 | 2022-03-31 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
| WO2022094271A1 (en) * | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022101184A1 (en) * | 2020-11-11 | 2022-05-19 | Bayer Aktiengesellschaft | N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2022235900A1 (en) * | 2021-05-06 | 2022-11-10 | Celgene Corporation | Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)- 2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1- oxoisoindoline-5-carboxamide |
| WO2023183601A1 (en) * | 2022-03-24 | 2023-09-28 | Scorpion Therapeutics, Inc. | Methods of synthesizing egfr inhibitors |
| CN119264091B (zh) * | 2024-09-04 | 2025-05-27 | 康龙化成手性医药技术(宁波)有限公司 | 一种1,5-双取代-3-氧杂双环[3.1.1]庚烷的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| US7211573B2 (en) | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
| DE102006033140A1 (de) | 2006-07-18 | 2008-01-24 | Merck Patent Gmbh | Aminoindazolharnstoffderivate |
| EP2151431A4 (en) | 2007-04-27 | 2010-04-21 | Sumitomo Chemical Co | AMID CONNECTION AND ITS USE |
| BRPI0814777A2 (pt) | 2007-08-08 | 2015-03-03 | Glaxosmithkline Llc | Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica. |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| EP2443117B1 (en) * | 2009-06-15 | 2016-03-23 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| AR097325A1 (es) | 2013-08-13 | 2016-03-09 | Gruenenthal Gmbh | Pirroles anillados |
| WO2015175632A1 (en) * | 2014-05-13 | 2015-11-19 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN106715415B (zh) * | 2014-06-17 | 2019-06-14 | 拜耳制药股份公司 | 3-氨基-1,5,6,7-四氢-4h-吲哚-4-酮 |
| CA2969771A1 (en) | 2014-12-08 | 2016-06-16 | Bayer Pharma Aktiengesellschaft | Novel aryl-cyanoguanidine compounds |
| US10301306B2 (en) | 2014-12-15 | 2019-05-28 | Bristol-Myers Squibb Company | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors |
| UA122221C2 (uk) * | 2015-01-28 | 2020-10-12 | Байєр Фарма Акцієнгезелльшафт | 4Н-ПІРОЛО[3,2-c]ПІРИДИН-4-ОНОВІ ПОХІДНІ |
| WO2019081486A1 (en) * | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | 4H-PYRROLO [3,2-C] PYRIDIN-4-ONE DERIVATIVES |
-
2020
- 2020-04-22 TW TW109113538A patent/TWI849114B/zh active
- 2020-04-22 SG SG11202111304UA patent/SG11202111304UA/en unknown
- 2020-04-22 CR CR20210530A patent/CR20210530A/es unknown
- 2020-04-22 IL IL287390A patent/IL287390B1/en unknown
- 2020-04-22 EP EP20721196.2A patent/EP3959211A1/en active Pending
- 2020-04-22 WO PCT/EP2020/061176 patent/WO2020216781A1/en active Application Filing
- 2020-04-22 CN CN202311716707.8A patent/CN117986251A/zh active Pending
- 2020-04-22 MA MA055751A patent/MA55751A/fr unknown
- 2020-04-22 JO JOP/2021/0285A patent/JOP20210285A1/ar unknown
- 2020-04-22 CN CN202311714944.0A patent/CN117946100A/zh active Pending
- 2020-04-22 BR BR112021019998-5A patent/BR112021019998B1/pt active IP Right Grant
- 2020-04-22 PE PE2021001760A patent/PE20220254A1/es unknown
- 2020-04-22 KR KR1020217037778A patent/KR20220004103A/ko active Pending
- 2020-04-22 CA CA3137218A patent/CA3137218A1/en active Pending
- 2020-04-22 AU AU2020262221A patent/AU2020262221A1/en active Pending
- 2020-04-22 US US17/605,975 patent/US20220298157A1/en active Pending
- 2020-04-22 JP JP2021563175A patent/JP7641913B2/ja active Active
- 2020-04-22 GE GEAP202015804A patent/GEP20247648B/en unknown
- 2020-04-22 CN CN202080031189.4A patent/CN114127064B/zh active Active
- 2020-04-22 PH PH1/2021/552693A patent/PH12021552693A1/en unknown
- 2020-04-22 MX MX2021012987A patent/MX2021012987A/es unknown
-
2021
- 2021-10-19 EC ECSENADI202177614A patent/ECSP21077614A/es unknown
- 2021-10-20 CO CONC2021/0014022A patent/CO2021014022A2/es unknown
- 2021-10-21 CL CL2021002770A patent/CL2021002770A1/es unknown
- 2021-10-22 DO DO2021000216A patent/DOP2021000216A/es unknown
-
2024
- 2024-11-15 US US18/949,801 patent/US20250136599A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3959211A1 (en) | 2022-03-02 |
| ECSP21077614A (es) | 2021-11-30 |
| CA3137218A1 (en) | 2020-10-29 |
| PH12021552693A1 (en) | 2022-03-21 |
| KR20220004103A (ko) | 2022-01-11 |
| CN114127064B (zh) | 2023-12-26 |
| US20250136599A1 (en) | 2025-05-01 |
| DOP2021000216A (es) | 2022-05-15 |
| CN114127064A (zh) | 2022-03-01 |
| IL287390B1 (en) | 2025-07-01 |
| WO2020216781A1 (en) | 2020-10-29 |
| CN117986251A (zh) | 2024-05-07 |
| MA55751A (fr) | 2022-03-02 |
| JP7641913B2 (ja) | 2025-03-07 |
| CR20210530A (es) | 2021-12-23 |
| CN117946100A (zh) | 2024-04-30 |
| GEP20247648B (en) | 2024-07-25 |
| AU2020262221A1 (en) | 2021-11-18 |
| TW202106683A (zh) | 2021-02-16 |
| MX2021012987A (es) | 2022-04-01 |
| CL2021002770A1 (es) | 2022-05-27 |
| CO2021014022A2 (es) | 2022-03-29 |
| IL287390A (en) | 2021-12-01 |
| BR112021019998A2 (enrdf_load_stackoverflow) | 2021-12-07 |
| BR112021019998B1 (pt) | 2024-01-16 |
| US20220298157A1 (en) | 2022-09-22 |
| JP2022532850A (ja) | 2022-07-20 |
| TWI849114B (zh) | 2024-07-21 |
| PE20220254A1 (es) | 2022-02-16 |
| JOP20210285A1 (ar) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287390A (en) | h4-Pyrrolo [2,3-c]pyridin-4-one compounds | |
| ZA201705802B (en) | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives | |
| IL276802B1 (en) | Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones | |
| IL289186A (en) | Compounds of 4,4a,5,7,8,8a - hexapyrido[4,3-b][1,4]oxazin-3-one as inhibitors of magl | |
| IL272262A (en) | Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one | |
| IL289233A (en) | Compounds 4,4a,5,7,8,8a -hexapyrido[4,3-b][4-1]oxazin-3-one as magl inhibitors | |
| IL290445A (en) | [4,2,1]triazolo[5,1-c]quinazoline-5-amines | |
| IL257413A (en) | Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials | |
| ZA202100259B (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
| IL280513A (en) | Imidazo[2,1-B]pyridazines as TRK inhibitors | |
| IL280661A (en) | PYRROLO[2,3-B]PYRIDINE is mutated at position 4 as ERBB regulators that are useful in cancer therapy | |
| EP3976618A4 (en) | TRICYCLIC COMPOUNDS | |
| IL280122A (en) | Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors | |
| SG11202102363PA (en) | FURO[3,4-b]PYRROLE-CONTAINING BTK INHIBITOR | |
| IL289141A (en) | Compounds 7,8 dihydro-4h-pyrazolo[3,4-c]azepin-6-one | |
| HK40110212A (en) | 4h-pyrrolo[3,2-c]pyridin-4-one compounds | |
| HK40110192A (en) | 4h-pyrrolo[3,2-c]pyridin-4-one compounds | |
| HK40069903B (en) | 4h-pyrrolo[3,2-c]pyridin-4-one compounds | |
| HK40074720B (en) | [1,2,4]triazolo[1,5-C]quinazolin-5-amines | |
| HK40108124A (en) | 6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4] triazol-2-amine derivatives | |
| HK40047689B (en) | 6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4] triazol-2-amine derivatives | |
| HK40043303A (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| HK40027677A (en) | 1, 2-dihydro-3h-pyrazolo [3, 4-d]pyrimidin-3-one analogs | |
| HK40041290A (en) | Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors | |
| ZA201801639B (en) | Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials |